Top Financial names Dean Huge independent director, adds him to audit and compensation committees
Bitget2026/10/09 20:31Top Financial Group expanded its board to seven directors on Oct. 8, 2026. Dean Huge joined as an independent director, taking seats on the audit, compensation, nominating, corporate governance committees. Huge has led Belgra Fintech Holdings, London Gold, Innovation Beverage Group; previously served as CFO at Splash Beverage Group. Yuli Yan was appointed executive director, effective Oct. 8, 2026. Yan is director of business operations at HexaGaN, with prior roles at Arizona State University, Zoyce Inc. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Top Financial Group Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-108497), on October 09, 2026, and is solely responsible for the information contained therein.
- Top Financial Group expanded its board to seven directors on Oct. 8, 2026.
- Dean Huge joined as an independent director, taking seats on the audit, compensation, nominating, corporate governance committees.
- Huge has led Belgra Fintech Holdings, London Gold, Innovation Beverage Group; previously served as CFO at Splash Beverage Group.
- Yuli Yan was appointed executive director, effective Oct. 8, 2026.
- Yan is director of business operations at HexaGaN, with prior roles at Arizona State University, Zoyce Inc.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.
Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks
Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.
Crypto prices
More
